The 476th case: skin rash, edema, thrombocytopenia and anemia
10.3760/cma.j.issn.0578-1426.2020.03.019
- VernacularTitle: 第476例——皮疹、水肿、血小板减低、贫血
- Author:
Yangzhong ZHOU
1
;
Jiuliang ZHAO
;
Xiaoyu CAO
;
Ke ZHENG
;
Qingjun WU
;
Xiaofeng ZENG
Author Information
1. Department of Rheumatology and Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
- Publication Type:Journal Article
- Keywords:
Lupus erythematosus, systemic;
Thrombotic microangiopathy;
von Willebrand factor-cleaving protease
- From:
Chinese Journal of Internal Medicine
2020;59(3):250-252
- CountryChina
- Language:Chinese
-
Abstract:
The 21-year-old male patient was admitted to the Department of Rheumatology and Immunology at Peking Union Medical College Hospital with chief complaints of "skin rash for 1 year and edema for 2 months". He was diagnosed with systemic lupus erythematosus (SLE) with renal, cardiac and hematological involvement. Remission was not achieved after glucocorticoid pulse treatment. The patient experienced oliguria, malignant hypertension, accompanied by thrombocytopenia and low serum complements, and elevated lactate dehydrogenase and serum creatinine. Schistocytes were seen in the peripheral blood smear. Thrombotic microangiopathy (TMA) secondary to SLE was diagnosed. Though plasma exchange was partially effective, TMA could not be controlled yet. The activity of serum von Willebrand factor -cleaving protease (ADAMTS 13) was 100%, and ADAMTS 13 inhibitor was negative. Finally, remission of the disease was achieved after second glucocorticoid pulse therapy and rituximab treatment. At the 3-month follow-up, the patient′s condition was stable with mild anemia and normal platelet count. Patients with TMA secondary to SLE are heterogenous, while normal ADAMT 13 activity indicates poor prognosis. Early and aggressive treatment is important for disease control, and plasma exchange is helpful as a supportive care.
